Literature DB >> 26882083

Associations between Single-Nucleotide Polymorphisms in Corticotropin-Releasing Hormone-Related Genes and Irritable Bowel Syndrome.

Ayaka Sasaki1, Naoko Sato1, Naoki Suzuki2, Michiko Kano1,3, Yukari Tanaka1, Motoyori Kanazawa1, Masashi Aoki2, Shin Fukudo1.   

Abstract

UNLABELLED: Irritable bowel syndrome (IBS) is a common functional disorder with distinct features of stress-related pathophysiology. A key mediator of the stress response is corticotropin-releasing hormone (CRH). Although some candidate genes have been identified in stress-related disorders, few studies have examined CRH-related gene polymorphisms. Therefore, we tested our hypothesis that single-nucleotide polymorphisms (SNPs) in CRH-related genes influence the features of IBS.
METHODS: In total, 253 individuals (123 men and 130 women) participated in this study. They comprised 111 IBS individuals and 142 healthy controls. The SNP genotypes in CRH (rs28364015 and rs6472258) and CRH-binding protein (CRH-BP) (rs10474485) were determined by direct sequencing and real-time polymerase chain reaction. The emotional states of the subjects were evaluated using the State-Trait Anxiety Inventory, Perceived Stress Scale, and the Self-rating Depression Scale.
RESULTS: Direct sequencing of the rs28364015 SNP of CRH revealed no genetic variation among the study subjects. There was no difference in the genotype distributions and allele frequencies of rs6472258 and rs10474485 between IBS individuals and controls. However, IBS subjects with diarrhea symptoms without the rs10474485 A allele showed a significantly higher emotional state score than carriers.
CONCLUSIONS: These results suggest that the CRH and CRH-BP genes have no direct effect on IBS status. However, the CRH-BP SNP rs10474485 has some effect on IBS-related emotional abnormalities and resistance to psychosocial stress.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26882083      PMCID: PMC4755592          DOI: 10.1371/journal.pone.0149322

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


Introduction

Irritable bowel syndrome (IBS) is a widespread functional disorder of the lower gastrointestinal tract that is primarily characterized by abdominal pain and altered bowel habits (diarrhea and/or constipation) [1]. IBS is associated with impaired quality of life and excessive use of health care resources and has long been considered to be a stress-related disorder [2, 3]. Co-morbidity of psychological disorder and somatic co-morbidities have been reported in IBS [4, 5]. IBS patients reported more anxiety, depression, and perceived stress than healthy people [4]. The impact of stress and psychosocial factors on predisposition to IBS symptoms and their precipitation and maintenance highlights the importance of taking into consideration the effect of stress on the underlying molecular mechanisms [6, 7]. Some hypothalamic-pituitary-adrenal (HPA) axis-related genetic variation [8], including 11β-hydroxysteroid dehydrogenase type 1[9], glucocorticoid receptor [10], and mineralocorticoid receptor [11] gene polymorphisms, is known to be associated with the stress response. Corticotropin-releasing hormone (CRH), encoded by the CRH gene, is a key integrator of the stress response [12-14]. The response to stress in mammals is mediated through endocrine, autonomic, and behavioral systems via secretion of CRH by the paraventricular nucleus of the hypothalamus [15, 16]. This system is critical for survival but its chronic over-activity can lead to stress-related pathologies [17-19]. In this way, dysregulation of this system has been linked to a variety of stress-related disorders, including depression, post-traumatic stress disorder, suicidality, panic disorder, and alcohol consumption [20-27]. Components of the highly interrelated system of the HPA axis include not only CRH but also CRH receptors (CRH-R1/CRH-R2) and CRH-binding protein (CRH-BP) [14]. CRH-BP represents a passive ligand trap that binds to and neutralizes CRH, thereby terminating its biological actions, in contrast to its active receptor that initiates signal transduction on binding [28]. Furthermore, CRH-related peptides are expressed not only in the brain but also within the colon, where they activate enteric, endocrine, and immune cells and may be involved in colonic manifestations of IBS [1]. Recently, some candidate gene studies have identified an association between gene polymorphisms and IBS [29-32]. Most of the studies investigated the association of IBS with genetic variations in the serotonin (5-hydroxytryptamine) signaling system, immune system, or adhesion molecules [29-31]. Single-nucleotide polymorphisms (SNPs) in interleukin-10 (IL-10) and hydroxytryptamine receptor 2A were associated with diarrhea-predominant IBS in female patients [30]. IL-6, cadherin-1, and toll-like receptor-9 genes were associated with post-infectious IBS [29]. However, only a few gene studies have found positive evidence of CRH-related gene polymorphisms associated with IBS [32]. Polymorphisms in CRH-related peptide CRH-R1 and CRH-R1 haplotypes were suggested to moderate IBS and IBS bowel patterns in a previous study [32]. Although CRH-related peptides are clearly important in IBS, no study has clarified the role of gene polymorphisms in CRH and CRH-BP in IBS. Earlier studies suggested an association of CRH-BP gene polymorphisms with the antidepressant treatment response, major depressive disorder, and suicidal behavior in schizophrenia [33-35]. In rhesus macaques, a polymorphism in the CRH promoter region increases the risk of disorder in stress-exposed individuals [22]. Thus, the aim of this study was to investigate the associations between genetic variants of the CRH system and IBS. We had the following two hypotheses: 1) SNPs in the CRH and CRH-BP genes are different between IBS patients and healthy people; and 2) these selected SNPs in the CRH and CRH-BP genes influence the IBS endophenotype (bowel movement patterns and psychological abnormalities).

Materials and Methods

Subjects

The characteristics of the subjects are shown in . In total, 253 volunteers (130 women and 123 men) aged 22.0 ± 2.2 years (mean ± standard deviation [SD]) participated in the current study. They were all Japanese individuals recruited from universities in Sendai, Japan. IBS patients were diagnosed according to the Rome III criteria [36]. IBS patients were classified by their predominant bowel pattern: constipation, diarrhea, or mixed. There was no significant difference in age, sex ratio, and IBS status between the groups. This study was approved by the Ethics Committee of Tohoku University Graduate School of Medicine. All participants gave their written informed consent. Abbreviations: IBS, irritable bowel syndrome; SD, standard deviation. Among the 253 participants, 190 were included in a study of the polymorphisms of the 5-hydroxytryptamine transporter [37] and CRH-R1 polymorphic region [32]. However, those genes were completely different from the genes targeted in this study. The hypotheses in this study and the previous studies are different. The previous analysis does not impact on this study.

Psychometric Tests

The emotional states of the subjects were rated using the Self-rating Depression Scale (SDS) [38, 39], Perceived Stress Scale (PSS) [40, 41], and State-Trait Anxiety Inventory (STAI) [42, 43]. The SDS is a rating of affective, psychological, and somatic symptoms associated with depression, the PSS measures the perception of stress, and the STAI is a rating of two types of anxiety: state anxiety and trait anxiety.

Genotyping

Whole blood (10mL) was sampled from the median cubital vein of all subjects. DNA was extracted from the white blood cells using a standard protocol [32]. SNPs in CRH (rs28364015 and rs6472258) [22, 33] and CRH-BP (rs10474485) [33] were selected by considering previous reports, and minor allele frequencies were determined from a database [NCBI: http://www.ncbi.nlm.nih.gov/snp/]. CRH is encoded by the CRH gene, which is located on chromosome 8 and spans 2.34 kb. rs28364015 and rs6472258 are also located on chromosome 8 (position 67253453 and 67259033, respectively). CRH rs28364015 is a 5′ untranslated region variant, and rs6472258 is an intergenic variant. Further, CRH-BP is encoded by the CRH-BP gene, which is located on chromosome 5 and spans 16.76 kb. CRH-BP rs10474485 is located on chromosome 5: (position 76306609). rs10474485 is also intronic and is a non-coding transcript variant. The genotypes of the CRH and CRH-BP polymorphisms were determined by real-time polymerase chain reaction (PCR) (TaqMan assay). DNA samples from 40 participants were amplified by direct PCR to determine the positive controls. A 50-μL PCR reaction consisted of 0.2 μM of each primer, 1.25 U Primer STAR HS DNA polymerase, 200 μM deoxynucleoside triphosphate, and 1× Prime STAR buffer. After initial denaturation at 94°C for 4 min, amplification was performed using 35 cycles at 94°C for 1 min (denaturation), 60°C for 1 min (annealing), and 72°C for 1.5 min (elongation), followed by a final elongation step at 72°C for 7 min. Then, the amplified PCR products were purified from a 2% agarose gel using a QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany). Amplimers were directly sequenced using an ABI PRISM dRhodamineTM Terminator Cycle Sequencing Ready Reaction Kit (PE Applied Biosystems, Foster City, CA), and excess dye terminators were removed using CENTRI-SEP columns (Princeton Separations, Adelphia, NJ). Automated sequencing was performed on an ABI 3130 Genetic Analyzer (PE Applied Biosystems). All procedures were carried out according to the instructions of the manufacturers. Forward and reverse primers were used to sequence the PCR products. Using Primer3 Input version 0.4.0 (http://frodo.wi.mit.edu/primer3/), two CRH SNP (rs28364015 and rs6472258) and one CRH-BP SNP (rs10474485) oligonucleotide primer sets were designed. The forward primers were 5′-GCA GAA AGA TGG TGG GAC TC-3′ (rs28364015), 5′-AGG AGA ATC GCT TGA ACC TG-3′ (rs6472258), and 5′-GCA CCC AAA AGA GAG TTG TG-3′ (rs10474485). The reverse primers were 5′-TCT CTT GAC AGC TCG ATT GC-3′ (rs28364015), 5′-CTG GAT TGA ATT CCC TGT CC-3′ (rs6472258), and 5′-GGA GAG TCA ACA GGG GAA TTG-3′ (rs10474485). Similarly, rs6472258 and rs10474485 TaqMan probe sets were designed, and the participants were genotyped by real-time PCR. However, the TaqMan assay failed for rs28364015 because of the frequency of the C allele (0%). The PCR reactions consisted of 200 nM of each primer, 200 nM fluorogenic probe, 1× SsoAdvanced Probes Supermix, and distilled water (up to 10 μL). Automated sequencing was performed on a CFX 96TM Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., Tokyo, Japan).

Statistical Analysis

We used Haploview [44] to confirm the Hardy-Weinberg equilibrium. The effects of the genotypes or alleles of each SNP were compared between the IBS patients and controls using the χ2 test and Odds Ratio (OR) (95% confidence interval [CI]). Two-way analysis of variance with a post hoc test was performed to determine the association between the SNPs and the psychometric tests. Results are expressed as the mean ± SD. We considered p < 0.05 to be statistically significant, whereas a p-value < 0.1 was considered to be tendentially but not statistically, significant. Statistical analyses were performed using SPSS Statistic 22.0 (IBM, Inc., New York, NY).

Results

The genotype frequencies of the selected CRH and CRH-BP gene variations in the IBS patients and controls are shown in Table 2. There was no significant difference in the genotype frequencies of rs6472258 (p = 0.990, χ2 test) and rs10474485 (p = 0.969, χ2 test) between the patients and controls. Similarly, there was no significant difference in the allele frequencies of the rs6472258 T allele (p = 0.675, χ2 test) or G allele (p = 0.890, χ2 test), and rs10474485 C allele (p = 0.816, χ2 test) or A allele (p = 0.986, χ2 test) between the IBS patients and controls. Moreover, the results of the additional analysis (OR [95% CI]) in rs6472258, alleles are not associated with IBS, with an OR of 1.036 (95% CI, 0.629–1.71) for G allele and 1.015 (95% CI, 0.524–1.97) for T allele. Similarly, the allelic OR (95% CI) of rs10474485 were 1.000 (95% CI, 0.976–1.025) for A allele and 0.914 (95% CI, 0.427–1.956). There was no difference in statistical results between genotype or allele frequency and OR.
Table 2

Genotype Frequencies in the IBS Patients and Controls.

dbSNP rs#GenotypeIBS (%)Control (%)p value
Male (n = 47)Female (n = 64)Male (n = 76)Female (n = 66)IBS vs. control
rs6472258GG9 (8.1)10 (9.0)15 (10.6)9 (6.3)0.990
GT12 (10.8)20 (18.0)21 (14.8)19 (13.4)
TT26 (23.4)34 (30.6)40 (28.2)38 (26.8)
rs10474485AA7 (6.3)6 (5.4)7 (4.9)11 (7.7)0.969
AC16 (14.4)17 (15.3)21 (14.8)20 (14.1)
CC24 (21.6)41 (36.9)48 (33.8)35 (24.6)

Abbreviations: dbSNP, Single Nucleotide Polymorphism Database; IBS, irritable bowel syndrome.

Abbreviations: dbSNP, Single Nucleotide Polymorphism Database; IBS, irritable bowel syndrome. The psychometric scores of the IBS patients and controls are shown in Table 3. For the SDS, the score of the IBS patients was higher than that of the controls (p = 0.016). In addition, for the PSS, the score of the IBS patients was higher than that of the controls (p = 0.028). The STAI score was not significantly different between the two groups (State, p = 0.111; Trait, p = 0.115).
Table 3

Psychometric Scores.

IBSControlp value
Psychometric score, mean [SD]Male (n = 47)Female (n = 64)Total (n = 111)Male (n = 76)Female (n = 66)Total (n = 142)IBS vs. control
SDS40.2 [7.4]42.8 [6.9]41.7 [7.2]37.9 [7.4]40.8 [9.5]39.2 [8.6]0.016
PSS27.4 [8.5]29.6 [7.9]28.7 [8.2]24.4 [9.3]28.2 [9.3]26.1 [9.5]0.028
STAI (State)47.1 [9.0]44.8 [9.6]45.8 [9.4]42.6 [7.7]45.3 [11.8]43.9 [9.9]0.111
STAI (Trait)47.8 [11.0]49.5 [10.0]48.8 [10.4]46.1 [9.2]47.2 [12.7]46.6 [10.9]0.115

Abbreviations: IBS, irritable bowel syndrome; SD, standard deviation; SDS, Self-rating Depression Scale; PSS, Perceived Stress Scale; STAI, State-Trait Anxiety Inventory.

Abbreviations: IBS, irritable bowel syndrome; SD, standard deviation; SDS, Self-rating Depression Scale; PSS, Perceived Stress Scale; STAI, State-Trait Anxiety Inventory. In the analysis of all subjects (IBS patients + controls), rs10474485 A allele non-carriers showed a higher PSS score than carriers (F[1, 507] = 6.459, p = 0.012). There was a significant group (IBS vs. control) effect with the SDS (p = 0.014) and PSS (p = 0.030) scores. The mean (± SD) PSS score of A allele carriers was 25.56 (± 8.359), whereas that of non-carriers was 28.48 (± 9.303). The other psychometric scores were not significantly different (SDS, p = 0.112; State, p = 0.140; Trait, p = 0.143). In contrast, we analyzed the associations between rs6472258 (genotype and allele) and the psychometric scores, but there was no significant difference. Next, we analyzed IBS symptoms. In individuals with diarrhea symptoms, there was a significant difference in the PSS (F[1, 363] = 6.186, p = 0.018) and Trait (F[1, 589] = 6.192, p = 0.017) scores between rs10474485 A allele non-carriers and carriers (Fig 1A). The mean (± SD) PSS scores of A allele carriers vs. non-carriers were 24.75 (± 8.234) vs. 30.96 (± 7.252), and the mean Trait scores were 44.19 (± 6.804) vs. 52.09 (± 11.329), respectively. Also, in those with mixed symptoms, the mean (± SD) SDS score of rs10474485 A allele carriers was 39.75 (± 5.802), whereas that of non-carriers was 45.00 (± 6.585). This difference was significant (F[1, 207] = 5.193, p = 0.030) (Fig 1B). There was no significant difference for those with constipation symptoms. Moreover, the associations between rs6472258 (genotype and allele) and IBS subtypes were not significantly different.
Fig 1

IBS subtype and CRH-BP SNP.

We analyzed the associations between the SNPs and psychometric scores according to IBS subtype. (a) In individuals with diarrhea-type IBS, rs10474485 A allele non-carriers showed higher scores than carriers. There were significant differences in the PSS (p = 0.018) and Trait (p = 0.017) scores. (b) In addition, in the IBS group with mixed symptoms, a significant difference was observed in the SDS score (p = 0.030). There was no significant difference in the constipation group. *p < 0.05.

IBS subtype and CRH-BP SNP.

We analyzed the associations between the SNPs and psychometric scores according to IBS subtype. (a) In individuals with diarrhea-type IBS, rs10474485 A allele non-carriers showed higher scores than carriers. There were significant differences in the PSS (p = 0.018) and Trait (p = 0.017) scores. (b) In addition, in the IBS group with mixed symptoms, a significant difference was observed in the SDS score (p = 0.030). There was no significant difference in the constipation group. *p < 0.05. In addition, in analysis of the male subjects alone, significant group (IBS/control) × rs10474485 genotype (F[2, 167] = 3.180, p = 0.045) (Fig 2A) and group (IBS/control) × rs10474485 A allele (F[1, 309] = 5.821, p = 0.017) (Fig 2B) interaction were observed in the SDS score. However, there was no difference in the emotional scores of the male subjects with respect to the A allele (Fig 3A). In the female subjects, significant differences were observed in the PSS (F[1,360] = 4.931, p = 0.028) and State (F[1, 520] = 4.557, p = 0.035) scores with respect to the rs10474485 A allele (Fig 3B). The mean (± SD) PSS score of female A allele carriers was 26.87 (± 7.983), whereas that of non-carriers was 30.42 (± 8.843). The mean (± SD) State score of A allele carriers was 42.74 (± 10.091), whereas that of non-carriers was 46.72 (± 10.962). Analyses of rs28364015 did not indicate a significant difference in males or females.
Fig 2

Self-rating Depression Scale and the CRH-BP SNP.

We analyzed associations between the selected SNP (rs10474485) and psychometric scores according to sex. (a) In male subjects, a significant group (IBS/control) × rs10474485 genotype interaction (p = 0.045) was observed. (b) Further, there was a significant group (IBS/control) × rs10474485 A allele interaction (p = 0.017). *p < 0.05.

Fig 3

Sex differences in psychometric scores according to the CRH-BP SNP.

(a) In analysis of male subjects (IBS + control), there was no significant difference (SDS, p = 0.864; PSS, p = 0.177; State, p = 0.979; Trait; p = 0.976). (b) In contrast, female A allele non-carriers of rs10474485 showed significantly higher PSS (p = 0.028) and State of STAI (p = 0.035) scores and tended to have higher SDS (p = 0.083) and Trait of STAI (p = 0.078) scores than carriers. *p < 0.05.

Self-rating Depression Scale and the CRH-BP SNP.

We analyzed associations between the selected SNP (rs10474485) and psychometric scores according to sex. (a) In male subjects, a significant group (IBS/control) × rs10474485 genotype interaction (p = 0.045) was observed. (b) Further, there was a significant group (IBS/control) × rs10474485 A allele interaction (p = 0.017). *p < 0.05.

Sex differences in psychometric scores according to the CRH-BP SNP.

(a) In analysis of male subjects (IBS + control), there was no significant difference (SDS, p = 0.864; PSS, p = 0.177; State, p = 0.979; Trait; p = 0.976). (b) In contrast, female A allele non-carriers of rs10474485 showed significantly higher PSS (p = 0.028) and State of STAI (p = 0.035) scores and tended to have higher SDS (p = 0.083) and Trait of STAI (p = 0.078) scores than carriers. *p < 0.05. As for the CRH SNP rs6472258, there was a nonsignificant trend for a difference in the SDS score between G allele carriers and non-carriers (all subjects, F[1, 244] = 3.837, p = 0.051; male subjects, F[1, 171] = 3.180, p = 0.077). In the present study, all subjects (n = 40) whose DNA was analyzed with direct sequencing had the rs28364015 TT genotype and no subjects had the C allele. Therefore, we excluded rs28364015 from the analysis of the real-time PCR data.

Discussion

In the current study, we analyzed CRH-related peptide genetic variations in controls and patients with IBS, which is one of the representative disorders with stress-related pathophysiology. On the basis of previous studies and reports of the sexually dimorphic expression of CRH-related genes [45-48], sex differences would be expected in our study. Indeed, in the present study, the CRH-BP SNP rs10474485 had a significant effect on the PSS score, especially in female subjects. In addition, there was a significant gene × group interaction in the SDS score of males. It has been suggested that sex differences are important when considering genetic influences on IBS. Some previous studies suggested that the functions of hormone and genetic variations were connected to sex [45-49]. For example, a role for 5-hydroxytryptamine receptor 2B genotypes in impulsivity was shown in male subjects [45], and transcriptional regulation of the human CRH-BP gene promoter by estrogen receptors was reported [49]. Similarly, it is thought that the association between differences in sex hormones and gene polymorphisms are important. As CRH plays a dominant role in the HPA axis, the effect of sex differences on hormone and hypothalamic function must be investigated. For the CRH SNP rs6472258, a tendency for a difference in the SDS score between G allele carriers and non-carriers was found, which may have influenced the differences in the SDS score in male subjects. Significant results might have been observed with more subjects. Some studies have suggested that CRH-related gene variations are not associated with IBS per se, but that the IBS subgroup or patients’ comorbid anxiety is associated with polymorphisms [50-52]. IBS subjects with diarrhea showed a higher response (namely, more inhibition) than healthy controls to a CRH receptor antagonist [53]. Therefore, IBS subjects with diarrhea might be more responsive to CRH or CRH-related peptides than healthy controls. Here, the IBS subjects with diarrhea symptoms (diarrhea or a mix) showed significant differences in some emotion states according to the presence of the rs10474485 SNP. It is suggested that these CRH-BP polymorphisms might more strongly influence IBS patients with diarrhea symptoms. CRH is a major mediator to activate HPA axis in stress response. In contrast, CRH-BP reduces the effect of CRH [28]. If rs10474485 A allele make the CRH-BP effects increase, CRH function may be more interfered with. Thereby, it is suggested that HPA axis activity attenuated, and stress response decreased. As a result, it is thought that psychometric scores might decrease when individuals have A allele. In the present study, the CRH G and CRH-BP A alleles were minor alleles. According to previous studies of stress-related disorders, CRH-related gene-specific polymorphisms appeared to protect against adult depressive symptoms [54, 55]. Subjects without the minor alleles of the selected SNPs showed higher psychometric scores than minor allele carriers. CRH exaggerates various stress responses, such as anxiety. Conversely, human CRH-BP binds to CRH and prevent activation of CRH receptors, thereby, reduce high activity with CRH [56]. In rodents, CRH-BP cells are concentrated within a hypothalamic circuit involved in mediating neuroendocrine and autonomic responses to stress [57]. CRH-BP expression downregulates the HPA axis by interfering with CRH, and the stress responses converge [28]. Here, CRH-BP rs10474485 was not directly related to IBS. However, the selected CRH-BP polymorphism was found to be in linkage disequilibrium with the CRH-BP SNPs rs10055255 (r2 = 0.410, D′ = 0.928) and rs1875999 (r2 = 0.410, D′ = 0.928) in the 1000 Genomes Project of Japanese individuals in Tokyo [the 1000 Genomes Browsers: http://browser.1000genomes.org/]. Homozygosity of the rs10055255 minor allele (TT) was associated with fewer incidences of post-traumatic stress disorder and depressive symptoms in post-intensive care units [58]. Under a condition of stress manipulation, individuals homozygous for the rs10055255 minor allele (TT) were noted to show high stress-induced alcohol craving, tension, and negative mood compared with their pre-stress condition. During the neutral imagery condition, there was no effect, but the post-stress rating was lower than that of pre-stress [59]. Thus, this SNP (rs10055255) may only show the differential effects of stress responses under a stressful situation. However, because our study was not conducted under stress conditions, the rs10055255 SNP was not selected. Nonetheless, it is suggested that CRH-BP polymorphisms influence stress responses during stress manipulation. In addition, the rs1875999 major allele (T) was more common in unipolar patients [60], and its minor allele (C) was associated with both heroin and cocaine addiction [61]. At present, the functionality of rs1875999 is unknown and the directionality of the role of the alleles in the stress response is not consistent. Accordingly, we did not select this SNP in this study. However, it is thought that this SNP has an inhibitory role in the development of stress-related neuropsychiatric disorders. Therefore, it is conceivable that a functional increase may occur in the CRH-BP produced by the CRH-BP rs10474485 minor allele and that the activity of the HPA axis may decrease. In other words, there may be protective effects of minor CRH/CRH-BP gene variants on the stress response. Although identified in the rhesus monkey [22], the genetic variant of the rs28364015 SNP has not been identified in the Japanese population. The present study is the first to try to identify this polymorphism in Japanese individuals. However, the results were negative. Regardless of the limited number of subjects (40 individuals), the possibility of finding this variation is considered to be very low. There are some limitations to this study. First, we did not have a sufficient number of samples to investigate SNPs. A future direction would be to collect more samples and to explore more SNPs in CRH, CRH-BP, CRH-R1, and CRH-R2. Moreover, because the average age of all subjects was low (22.0 ± 2.2 years), it is thought that the present data could not be extrapolated to the entire IBS population. However, a meta-analysis study showed that there was not significant difference in the prevalence of IBS between different age bands [62]. Therefore, it is thought that the subjects used in the present study were representative as an IBS group. Second, IBS severity was not explored. In the future, the association between disease severity and polymorphisms should be explored. Third, the rs6472258 and rs10474485 SNPs selected in this study are intronic. The rs6472258 SNP is located upstream of CRH gene exon 1. Similarly, rs10474485 is located downstream of CRH-BP gene exon 7 (Ensembl Genome Browser: http://www.asia.ensembl.org/). The effects of these areas on the transcriptional activity and protein expression of the CRH/CRH-BP genes are not clear. However, in a previous study, CRH receptor-1 SNPs located in the intron around exon 2 were associated with IBS [32]. Therefore, there may be a possibility that intronic SNPs can regulate the function of the CRH/CRH-BP genes. In any future study, the role of CRH genes in the endophenotype of IBS should be explored. In conclusion, our study suggests that CRH-BP gene polymorphisms had some effect on IBS-related psychological abnormalities. In contrast, we could not detect the associations between the CRH/CRH-BP genes and IBS status per se. Further evidence for a general role of CRH and CRH-BP gene polymorphisms in stress-related disorders is required.
Table 1

Sample Characteristics.

IBS (n = 111)Control (n = 142)
Male4776
Female6466
Age, years [SD]21.9 [2.0]22.0 [2.3]
IBS subtype
Constipation330
Diarrhea460
Mixed320

Abbreviations: IBS, irritable bowel syndrome; SD, standard deviation.

  56 in total

1.  Functional CRH variation increases stress-induced alcohol consumption in primates.

Authors:  Christina S Barr; Rachel L Dvoskin; Manisha Gupte; Wolfgang Sommer; Hui Sun; Melanie L Schwandt; Stephen G Lindell; John W Kasckow; Stephen J Suomi; David Goldman; J Dee Higley; Markus Heilig
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-17       Impact factor: 11.205

2.  Association of polymorphisms in genes regulating the corticotropin-releasing factor system with antidepressant treatment response.

Authors:  Elisabeth B Binder; Michael J Owens; Wei Liu; Todd C Deveau; A John Rush; Madhukar H Trivedi; Maurizio Fava; Bekh Bradley; Kerry J Ressler; Charles B Nemeroff
Journal:  Arch Gen Psychiatry       Date:  2010-04

3.  Combined effects of exonic polymorphisms in CRHR1 and AVPR1B genes in a case/control study for panic disorder.

Authors:  Martin E Keck; Nikola Kern; Angelika Erhardt; Paul G Unschuld; Marcus Ising; Daria Salyakina; Marianne B Müller; Carolin C Knorr; Roselind Lieb; Christa Hohoff; Petra Krakowitzky; Wolfgang Maier; Borwin Bandelow; Jürgen Fritze; Jürgen Deckert; Florian Holsboer; Bertram Müller-Myhsok; Elisabeth B Binder
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2008-10-05       Impact factor: 3.568

Review 4.  Psychotropic agents in functional gastrointestinal disorders.

Authors:  Madhusudan Grover; Douglas A Drossman
Journal:  Curr Opin Pharmacol       Date:  2008-09-09       Impact factor: 5.547

5.  Elevated plasma corticotrophin-releasing hormone levels in veterans with posttraumatic stress disorder.

Authors:  C S de Kloet; E Vermetten; E Geuze; E G W M Lentjes; C J Heijnen; G K Stalla; H G M Westenberg
Journal:  Prog Brain Res       Date:  2008       Impact factor: 2.453

6.  Impact of serotonin transporter gene polymorphism on brain activation by colorectal distention.

Authors:  S Fukudo; M Kanazawa; T Mizuno; T Hamaguchi; M Kano; S Watanabe; Y Sagami; T Shoji; Y Endo; M Hongo; Y Itoyama; K Yanai; M Tashiro; M Aoki
Journal:  Neuroimage       Date:  2009-05-06       Impact factor: 6.556

Review 7.  Functional gastrointestinal disorders as a public health problem.

Authors:  N J Talley
Journal:  Neurogastroenterol Motil       Date:  2008-05       Impact factor: 3.598

8.  Protective effect of CRHR1 gene variants on the development of adult depression following childhood maltreatment: replication and extension.

Authors:  Guilherme Polanczyk; Avshalom Caspi; Benjamin Williams; Thomas S Price; Andrea Danese; Karen Sugden; Rudolf Uher; Richie Poulton; Terrie E Moffitt
Journal:  Arch Gen Psychiatry       Date:  2009-09

9.  Serotonin transporter promoter variant: Analysis in Indian IBS patients and control population.

Authors:  Arbab Sikander; Satya Vati Rana; Saroj Kant Sinha; Kaushal Kishor Prasad; Sunil K Arora; Sanjeev Kumar Sharma; Kartar Singh
Journal:  J Clin Gastroenterol       Date:  2009 Nov-Dec       Impact factor: 3.062

10.  Common genetic origins for EEG, alcoholism and anxiety: the role of CRH-BP.

Authors:  Mary-Anne Enoch; Pei-Hong Shen; Francesca Ducci; Qiaoping Yuan; Jixia Liu; Kenneth V White; Bernard Albaugh; Colin A Hodgkinson; David Goldman
Journal:  PLoS One       Date:  2008-10-31       Impact factor: 3.240

View more
  5 in total

Review 1.  Don't stress about CRF: assessing the translational failures of CRF1antagonists.

Authors:  Samantha R Spierling; Eric P Zorrilla
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

2.  Corticotropin-releasing hormone receptor 1 (CRH-R1) polymorphisms are associated with irritable bowel syndrome and acoustic startle response.

Authors:  Alexa Orand; Bruce Naliboff; Malin Gadd; Wendy Shih; Tiffany Ju; Angela P Presson; Emeran A Mayer; Lin Chang
Journal:  Psychoneuroendocrinology       Date:  2016-07-19       Impact factor: 4.905

Review 3.  Corticotropin-releasing hormone-binding protein and stress: from invertebrates to humans.

Authors:  Kyle D Ketchesin; Gwen S Stinnett; Audrey F Seasholtz
Journal:  Stress       Date:  2017-05-18       Impact factor: 3.493

Review 4.  The Increased Level of Depression and Anxiety in Irritable Bowel Syndrome Patients Compared with Healthy Controls: Systematic Review and Meta-analysis.

Authors:  Changhyun Lee; Eunyoung Doo; Ji Min Choi; Seung-Ho Jang; Han-Seung Ryu; Ju Yup Lee; Jung Hwan Oh; Jung Ho Park; Yong Sung Kim
Journal:  J Neurogastroenterol Motil       Date:  2017-07-30       Impact factor: 4.924

5.  Evidence-based clinical practice guidelines for irritable bowel syndrome 2020.

Authors:  Shin Fukudo; Toshikatsu Okumura; Masahiko Inamori; Yusuke Okuyama; Motoyori Kanazawa; Takeshi Kamiya; Ken Sato; Akiko Shiotani; Yuji Naito; Yoshiko Fujikawa; Ryota Hokari; Tastuhiro Masaoka; Kazuma Fujimoto; Hiroshi Kaneko; Akira Torii; Kei Matsueda; Hiroto Miwa; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2021-02-04       Impact factor: 7.527

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.